A Study of SGB-9768 in Patients with Complement-mediated Kidney Diseases
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorSuzhou Sanegene Bio Inc.
About this trial
This study looks at how well and safely SGB-9768 works for patients with certain kidney diseases: primary IgA nephropathy, C3 glomerulopathy, and immune complex-related membranoproliferative glomerulonephritis. It's a phase 2 trial done at several locations where both patients and doctors know what treatment is being given.
Eligibility criteria
Qualifiers
Aged ≥18 years
Weight ≥40 kg, with a body mass index (BMI) between 15 and 35 kg/m²
Biopsy-confirmed diagnosis of primary IgA nephropathy, C3 glomerulopathy or IC-MPGN, accompanied by C3 deposition in the glomeruli.
Urine protein-to-creatinine ratio (UPCR) ≥0.75 g/g
Disqualifiers
Kidney biopsy indicates more than 50% tubular atrophy or interstitial fibrosis.
Kidney biopsy shows more than 50% formation of glomerular crescents, or clinical signs suggestive of rapidly progressive glomerulonephritis.
IgA nephropathy, C3 glomerulopathy, or IC-MPGN secondary to other diseases
Presence of other systemic diseases or kidney diseases that may cause proteinuria
Trial design
Treatments tested in this trial
- SGB-9768
Treatment groups
38 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov